Epidemiological Impact of Increasing Vaccination Coverage Rate and Re-Vaccination on Pneumococcal Disease in Older Adults in Germany DOI Creative Commons
Oluwaseun Sharomi, Marion de Lepper,

Sarah Mihm-Sippel

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(5), P. 475 - 475

Published: April 28, 2025

Background/Objectives: The clinical impact of replacing the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for vaccination older (≥60 years) and at-risk German adults with either 20-valent (PCV20) or 21-valent (V116) conjugate (PCV) was evaluated. Methods: An age- serotype-specific transmission model adapted to Germany evaluate V116 versus PCV20 on disease (PD) incidence, including invasive (IPD) inpatient outpatient non-bacteremic pneumonia, over 10 years. A reference strategy (PPSV23 at a constant 30% coverage rate (VCR)) compared against eight strategies varying by PCV (PCV20 vs. V116), VCR (30% 60%), without revaccination previously PPSV23-vaccinated (0% 50% revaccination). Results: Vaccination initially decreased PD but incidence returned pre-vaccine levels after five years, respectively. Increasing 60% prevented this resurgence. At 10-year time horizon, reduced IPD cases 9%, NBPP 10%, 7% strategy. these 6%, 5%, 4%, revaccinating further 14% 13% V116, 9% PCV20. Conclusions: strategically significantly enhanced effectiveness vaccines, showing greater overall reductions in PPSV23.

Language: Английский

Epidemiological Impact of Increasing Vaccination Coverage Rate and Re-Vaccination on Pneumococcal Disease in Older Adults in Germany DOI Creative Commons
Oluwaseun Sharomi, Marion de Lepper,

Sarah Mihm-Sippel

et al.

Vaccines, Journal Year: 2025, Volume and Issue: 13(5), P. 475 - 475

Published: April 28, 2025

Background/Objectives: The clinical impact of replacing the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for vaccination older (≥60 years) and at-risk German adults with either 20-valent (PCV20) or 21-valent (V116) conjugate (PCV) was evaluated. Methods: An age- serotype-specific transmission model adapted to Germany evaluate V116 versus PCV20 on disease (PD) incidence, including invasive (IPD) inpatient outpatient non-bacteremic pneumonia, over 10 years. A reference strategy (PPSV23 at a constant 30% coverage rate (VCR)) compared against eight strategies varying by PCV (PCV20 vs. V116), VCR (30% 60%), without revaccination previously PPSV23-vaccinated (0% 50% revaccination). Results: Vaccination initially decreased PD but incidence returned pre-vaccine levels after five years, respectively. Increasing 60% prevented this resurgence. At 10-year time horizon, reduced IPD cases 9%, NBPP 10%, 7% strategy. these 6%, 5%, 4%, revaccinating further 14% 13% V116, 9% PCV20. Conclusions: strategically significantly enhanced effectiveness vaccines, showing greater overall reductions in PPSV23.

Language: Английский

Citations

0